Innovationen in der Behandlung der juvenilen idiopathischen Arthritis

Viele Innovationen der Rheumatologie, Dermatologie und Gastroenterologie sind mittlerweile auch in der Therapie von Kindern angekommen. Hierzu zählen Biologika, immunologische Targets sowie sog. „small molecules“, die wie die Januskinase-Inhibitoren gezielt in den Entzündungsprozess eingreifen. In der Kinderrheumatologie sollen die sich daraus ergebenden Optionen mithilfe von „Treat to target“-Therapie-Protokollen zu einem besseren Outcome führen.

Schlüsselwörter

juvenilen idiopathischen Arthritis - NSAR - TNF-Inhibitoren - Interleukin-Inhibitoren - targeted synthetic small molecules

• Literatur

• 1 Lovell DJ, Giannini EH, Reiff A. et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000; 342: 763-769
• 2 Lovell DJ, Ruperto N, Goodman S. Pediatric Rheumatology Collaborative Study Group, Pediatric Rheumatology International Trials Organisation. et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008; 359: 810-820
• 3 Brunner HI, Ruperto N, Tzaribachev N. et al. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Ann Rheum Dis 2017; 77: 21-29
• 4 Kremer JM, Bloom BJ, Breedveld FC. et al. The safety and efficacy of a JAK in – inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009; 60: 1895-1905
• 5 Oommen PT, Schütz C. et al. S2k-Leitlinie – Therapie der Juvenilen Idiopathischen Arthritis. AWMF-Register Nr. 027/020. Accessed October 03, 2022 at: https://www.awmf.org/uploads/tx_szleitlinien/027–020l_S2k_Juvenile_Idiopathische_Arthritis_2020–10.pdf
• 6 Horneff G, Klein A, Ganser G. et al. Protocols on classification, monitoring and therapy in children’s rheumatology (PRO-KIND): results of the working group Polyarticular juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2017; 15: 78
• 7 Rubin S, Ohana O, Goldberg O. et al. The efficacy and safety of intra-articular injection of triamcinolone acetonide versus triamcinolone hexacetonide for treatment of juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2022; 20: 5
• 8 Klein A, Kaul I, Foeldvari I. et al. Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate Registry. Arthritis Care Res (Hoboken) 2012; 64: 1349-1356
• 9 van Rossum MA, van Soesbergen RM, Boers M. et al. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis 2007; 66: 1518-1524
• 10 Ramanan AV, Dick AD, Jones AP. et al. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. N Engl J Med 2017; 376: 1637-1646
• 11 Horneff G, Seyger MMB, Arikan D. et al. Safety of Adalimumab in Pediatric Patients With Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn’s Disease. J Pediatr 2018; 201: 166-175
• 12 Becker I, Horneff G. Risk of Serious Infection in Juvenile Idiopathic Arthritis Patients Associated With Tumor Necrosis Factor Inhibitors and Disease Activity in the German Biologics in Pediatric Rheumatology Registry. Arthritis Care Res (Hoboken) 2017; 69: 552-556
• 13 Horneff G. Safety of biologic therapies for the treatment of juvenile idiopathic arthritis. Expert Opin Drug Saf 2015; 14: 1111-1126
• 14 Horneff G, Klein A, Oommen PT. et al. A Update on malignancies in children with juvenile idiopathic arthritis in the German BIKER Registry. Clin Exp Rheumatol 2016; 34: 1113-1120
• 15 Vastert SJ, de Jager W, Noordman BJ. et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol 2014; 66: 1034-1043
• 16 Ruperto N, Brunner HI, Quartier P. et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367: 2396-2406
• 17 Atemnkeng Ntam V, Klein A, Horneff G. Safety and efficacy of anakinra as first-line or second-line therapy for systemic onset juvenile idiopathic arthritis – data from the German BIKER registry. Expert Opin Drug Saf 2021; 20: 93-100
• 18 De Benedetti F, Brunner HI, Ruperto N. et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367: 2385-2395
• 19 Brunner HI, Ruperto N, Zuber Z. et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 2015; 74: 1110-1117
• 20 Ruperto N, Lovell DJ, Quartier P. et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008; 372: 383-391
• 21 McInnes IB, Byers NL, Higgs RE. et al. Comparison of baricitinib, upadacitinib, and Tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther 2019; 21: 183
• 22 Consolaro A, Giancane G, Schiappapietra B. et al. Clinical outcome measures in juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2016; 14: 23
• 23 Horneff G, Becker I. Definition of improvement in juvenile idiopathic arthritis using the juvenile arthritis disease activity score. Rheumatology (Oxford) 2014; 53: 1229-1234
• 24 Kumar S, Kunhiraman DS, Rajam L. Application of the Yamaguchi criteria for classification of “suspected” systemic juvenile idiopathic arthritis (sJIA). Pediatr Rheumatol Online J 2012; 10: 40
• 25 Hinze CH, Holzinger D, Lainka E. et al. Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany. Pediatr Rheumatol Online J 2018; 16: 7
• 26 Hospach A, Trauzeddel R, Windschall D. et al. Protokolle zur Klassifikation, Überwachung und Therapie in der Kinderrheumatologie (PRO-KIND): Enthesitis-assoziierte Arthritis. Ergebnisse der Arbeitsgruppe Enthesitis-assoziierte Arthritis in der GKJR-Kommission PRO-KIND. Arthritis und Rheuma 2018; 38: 132-140
• 27 Klein A, Minden K, Hospach A. et al. Treat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis. Ann Rheum Dis 2020; 79: 969-974